A5048652672- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Metastasis and carcinoma case studies
- Childhood Cancer Survivors' Quality of Life
- Gastrointestinal Tumor Research and Treatment
- Thyroid Disorders and Treatments
- Gestational Trophoblastic Disease Studies
- Radiopharmaceutical Chemistry and Applications
- Metabolism, Diabetes, and Cancer
- Helicobacter pylori-related gastroenterology studies
- Parathyroid Disorders and Treatments
- Ovarian cancer diagnosis and treatment
- Gastric Cancer Management and Outcomes
- Medical Imaging Techniques and Applications
- Pituitary Gland Disorders and Treatments
- Atomic and Subatomic Physics Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lanthanide and Transition Metal Complexes
- Cancer Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Bone health and treatments
- Uterine Myomas and Treatments
- Breast Lesions and Carcinomas
Humboldt-Universität zu Berlin
2019-2024
Freie Universität Berlin
2019-2024
Charité - Universitätsmedizin Berlin
2015-2024
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2023
European Neuroendocrine Tumor Society
2018
Centre Virchow-Villermé
2015-2016
DRK Kliniken Berlin
2015
Max Delbrück Center
2013
Both the European Neuroendocrine Tumor Society (ENETS) and International Union for Cancer Control/American Joint Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging systems pancreatic neuroendocrine neoplasms. This study aims to identify most accurate useful system The included 1072 patients who had undergone previous surgery their cancer which at least 2 years of follow-up from 1990 2007 was available. Data on 28 variables were collected, performance two compared...
Neuroendocrine tumors (NETs) of the gastroenteropancreatic (GEP) system comprise a rare but challenging group malignant neoplasms and occur at virtually any site GEP system. In 2006, new TNM classification was proposed for staging grading upper NETs.The prognostic relevance analyzed retrospectively in 202 patients from referral center with histologically proven foregut NET. Patients were classified according to previous systems classification. Survival data acquired statistical analyses...
Abstract BACKGROUND: Prognostic classification of neuroendocrine tumor (NET) patients is difficult due to the complexity current systems. A recent proposal for a tumor‐node‐metastasis (TNM) and grading system based on proliferative fraction proved valid in NETs foregut origin. The purpose this study was test efficacy TNM staging midgut hindgut NETs. METHODS: Two hundred seventy with histologically proven were investigated. Epidemiological, clinicopathological, tumor‐specific data at initial...
A key issue in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is early identification and prediction of disease progression. Clinical evaluation imaging are limited due to the lack sensitivity indolence. We assessed NETest as a predictive prognostic marker progression long-term follow-up study.GEP-NETs (n = 34) followed for median 4 years (2.2-5.4) were evaluated. WHO tumor grade/stage grade 1: n 17, 2: 14, 3: 1 (for 2, no was available); 31 (91%) stage IV. Baseline longitudinal...
Malnutrition is a common problem in oncological diseases, influencing treatment outcomes, complications, quality of life and survival. The potential role malnutrition has not yet been studied systematically neuroendocrine neoplasms (NEN), which, due to their growing prevalence additional therapeutic options, provide an increasing clinical challenge diagnosis management. aim this cross-sectional observational study, which included long-term follow-up, was therefore define the 203 patients...
Background: The World Health Organization (WHO) and the American Joint Cancer Committee (AJCC) modified grading of pancreatic neuroendocrine neoplasms from a three-tier (WHO-AJCC 2010) to four-tier system by introducing novel category NET G3 2017). Objectives: This study aims at validating WHO-AJCC 2017 identifying most effective system. Method: A total 2,102 patients were enrolled; entry criteria were: (i) patient underwent surgery; (ii) least 2 years follow-up; (iii) observation time up...
Well-differentiated grade 3 neuroendocrine tumors (NET G3) have been distinguished from poorly differentiated carcinomas (NEC) in the most current WHO classifications. Commonly applied first-line chemotherapy protocols with cisplatin or carboplatin combination etoposide (PE) are less effective NET G3 than NEC. Suggested alternative treatment not studied therapy of so far. We performed a retrospective analysis patients databases German cancer centers. Out 142 patients, 136 received palliative...
<b><i>Background:</i></b> Somatostatin analogues (SSA) are widely used in the treatment of patients with functioning and non-functioning neuroendocrine tumours (NET). The aim our investigation was to evaluate antiproliferative effect SSA pancreatic NET. <b><i>Methods:</i></b> We retrospectively analysed records 43 NET treated at clinic octreotide long-lasting release as a first-line therapy. study investigate overall best response according...
The aim of the present study was to evaluate frequency, clinical spectrum, and treatment myocardial metastases in patients with histologically proven neuroendocrine tumors by analysis our database literature review. on cardiac published from 1973 reviewed for age, sex, primary tumor localization, metastases, symptoms, complications, treatment, diagnostic methods, histology. Patient records institution were analyzed retrospectively detected any means detailed patient histories are given. 4...
Placental growth factor (PlGF), a VEGF-homolog implicated in tumor angiogenesis and adaptation to antiangiogenic therapy, is emerging as candidate target malignancies. Here, we addressed the expression, function, prognostic value of PlGF neuroendocrine tumors (NETs). was determined NET patients' sera collected retrospectively ( n =88) prospectively =87) using Roche-Elecsys correlated with clinicopathological data. Tumoral evaluated by immunohistochemistry, effects on proliferation migration...
Patients with small intestinal neuroendocrine tumors (siNETs) frequently present emergently due to bowel ischemia or obstruction. The influence of emergency surgery on the prognosis siNET remains controversial. aim this study was investigate association between type presentation (emergency/elective) and oncological outcome.
Although gastric neuroendocrine neoplasias (gNEN) are an orphan disease, their incidence is rising. The heterogeneous clinical course powers the ongoing discussion of most appropriate classification system and management. Prognostic relevance proposed classifications was retrospectively analysed in 142 patients from a single tertiary referral centre. Baseline, management survival data were acquired for statistical analyses. distribution according to clinicopathological typification gNEN-1 (n...
Background: The De Ritis ratio (aspartate aminotransferase [AST]/alanine [ALT]) has demonstrated prognostic value in various cancer entities. We evaluated the capability of patients with metastatic neuroendocrine tumors (NET) undergoing peptide receptor radionuclide therapy (PRRT). Methods: Unicentric, retrospective analysis 125 NET PRRT [177Lu]Lu-DOTATOC (female: 37%; median age: 66 years; G1+G2 NET: 95%). regarding progression-free survival (PFS) was analyzed univariable and multivariable...
Background: Rapid quantification of liver metastasis for diagnosis and follow-up is an unmet medical need in patients with secondary malignancies. We present a 3D-quantification model neuroendocrine metastases (NELM) using gadoxetic-acid (Gd-EOB)-enhanced MRI as useful tool multidisciplinary cancer conferences (MCC). Methods: Manual 3D-segmentations NELM livers (149 278 Gd-EOB scans) were used to train neural network (U-Net architecture). Clinical usefulness was evaluated another 33 who...
Objectives The objective of this study was to investigate the efficacy and tolerability 5-fluorouracil–oxaliplatin (FOLFOX) in advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Methods Retrospective analysis consecutive 72 GEP-NENs treated with FOLFOX between 2005 2016 at a single German referral center for NENs performed. We assessed treatment response by evaluation criteria solid tumors 1.0 criteria, progression-free survival Kaplan-Meyer method, risk factor...
Osteopontin (OPN), also called secreted phosphoprotein 1 (SPP1) is a matricellular glycoprotein whose expression elevated in various types of cancer and which has been shown to be involved tumorigenesis metastasis many malignancies. Its role neuroendocrine neoplasms (NEN) remains established. The aim the study was analyze plasma concentrations OPN patients with NEN explore its diagnostic prognostic value as clinical biomarker.OPN were measured total 38 histologically proven at three...
The impact on the survival of bone metastases (BM) in patients with neuroendocrine tumor (NET) is a matter debate. BM have key role causing symptoms and decreasing patients' quality life. Although mechanisms development are not completely clear, it now well understood that Receptor Activator Nuclear factor Kappa-B-/Ligand (RANK/RANKL)/osteoprotegerin (OPG) pathway plays relevant role.To characterize RANK/RANKL/OPG affected NET.Two cohorts 15 each were enrolled study; one cohort was NET...
Pancreatic neuroendocrine tumours (pNETs) represent rare neoplasms of all NETs often presenting without functional activity. Many sporadic non-functioning pNET patients are already metastatic at the time diagnosis, and therapeutic approach to such is mostly palliative. In this international, multicentre, retrospective cohort study, we assessed prognostic value a set anthropometric, clinical, biochemical, radiological pathological parameters baseline impact strategies on survival with grade...